Reshape Lifesciences Inc (RSLS) Return on Assets ROA from the first quarter of 2026 to first quarter of 2024 and for the year 2026, Average High and Low, Fundamental Ratios from Mar 31 2026 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Reshape Lifesciences Inc  (NASDAQ: RSLS)


Reshape Lifesciences Inc's ROA from the first quarter of 2026 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Reshape Lifesciences Inc's ROA in the first quarter of 2026?
Reshape Lifesciences Inc recorded a cumulative net loss of $-10 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -144.83%.

However, within the Healthcare sector 853 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4488.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Mar 31 2026)
I. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Total Assets Change -17.48 % 25.47 % -17.57 % -21.24 % 15.75 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -10 -11 -3 -3 -3
Return On Assets (TTM) -144.83 % -144.76 % -40.37 % -41.2 % -36.8 %
RSLS's Total Ranking # 4488 # # 4711 # 4682 # 4775
Total Assets (TTM) in million 10 7 4 6 12
Seq. Total Assets Change 44.57 % 59.7 % -31.95 % -47.48 % 119.82 %
Seq. Net Income Change - - - - -

RSLS's 5 Years Annual ROA >> Back to RSLS Management Effectiveness >> Compare RSLS ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 406
Sector # 854
Overall # 4442

Return On Assets Statistics
High Average Low
-0.21 %
-118.76 %
-381.32 %
  (Sep 30 2025)



  News about Reshape Lifesciences Inc Return on Assets ROA

ReShape Lifesciences Pioneers Innovative Approaches in Weight Loss and Diabetes Management with New Health Canada Approval and Strategic Research Collaborations

In a remarkable leap forward for obesity management and diabetes treatment, ReShape Lifesciences has recently garnered Health Canada’s approval for its next-generation Lap-Band 2.0, equipped with the innovative FLEX Technology. Designed with the patient s experience at the forefront, this advanced device promises to enhance safety, comfort, and efficacy during weight-loss procedures. The approval is a significant milestone for ReShape, as it not only reflects the company s commitment to improving patient outcomes but also aligns with its vision of utilizing state-of-the-art technology to tackle pressing health challenges.The FLEX Technology incorporated in the Lap-Band 2.0 aims to redefine the patient experience by allowing for greater flexibility and adaptability during and after the procedure. By focusing on optimizing patient safety and recovery, ReShape Lifesciences is taking a crucial step toward creating more effective solutions that cater to individual needs. This approval comes at a time when demand for innovative weight-loss solutions has surged, emphasizing the need for devices that are both effective and user-friendly.



Financial Statements
Reshape Lifesciences Inc's Assets $ 10 million RSLS's Balance sheet
Reshape Lifesciences Inc's Income $ -1 million Quarterly RSLS's Income Statement
RSLS's Income by Division See RSLS's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020
Y / Y Total Assets Change -55.05 % -4.3 % -79.46 % 46.4 % -6.54 %
Total Assets in million 5 11 11 54 37
Y / Y Net Income Change - - - - -
Net Income in million -7 -11 -46 -62 -22
Annual Return On Assets -148.76 % -106.79 % -414.77 % -114.15 % -58.36 %

RSLS's 5 Years Annual ROA >> Back to RSLS Management Effectiveness >> Compare RSLS ROA to its Competitors



More Return On Assets Ratios
RSLS's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RSLS's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RSLS's Competitors
Subscribers only: Roa for Reshape Lifesciences Inc's Suppliers
Subscribers only: Return On Assets for RSLS's Customers

You may also want to know
RSLS's Roi RSLS's Inventory Turnover Ratio RSLS's Growth Rates RSLS's Dividend Comparisons
RSLS's Profitability Ratios RSLS's Asset Turnover Ratio RSLS's Dividend Growth
RSLS's Roe RSLS's Valuation Ratios RSLS's Financial Strength Ratios RSLS's Dividend Payout Ratio



Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector ROA

Date modified: 2026-09-26T07:30:32+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.